ABUS · Arbutus Biopharma Corporation

Arbutus Biopharma’s Q1 2026 results reflect a dramatic inflection driven almost entirely by non-recurring litigation-related revenue: $178.7 million in license revenue from Genevant tied to the March 2026 settlement with Moderna. This one-time inflow transformed the Company from a $24.5 million net loss in Q1 2025 to $169.7 million net income, with diluted EPS flipping from ($0.13) to $0.87. Excluding this item, core operations remained lean — R&D spending dropped 54% year-over-year to $4.1 million due to strategic restructuring (workforce reduction, halted in-house research, and winding down clinical trials), while G&A rose modestly to $5.9 million, largely offset by cost-cutting, with higher legal fees linked to the Moderna settlement. The Company’s cash position improved to $95.2 million as of March 31, 2026, despite $8.1 million net cash used in operations — a figure inflated by one-time restructuring payments and partially offset by $11.5 million in stock option exercise proceeds. Importantly, the press release confirms receipt of the $178.7 million is expected in July 2026, meaning it is recorded as a $178.7 million license receivable on the balance sheet as of quarter-end, not yet in cash. Beyond financials, the FDA’s April 2026 Fast Track designation for imdusiran signals regulatory momentum for Arbutus’ lead HBV candidate, potentially accelerating development timelines and enhancing commercial prospects. With no forward guidance disclosed and no mention of updated cash runway or future revenue expectations beyond the pending settlement payment, investors must assess sustainability solely through the lens of pipeline progress and potential future IP monetization events.